Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis

A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study

J. Eduardo Sousa, MD, PhD; Marco A. Costa, MD, PhD; Alexandre Abizaid, MD, PhD; Amanda G.M.R. Sousa, MD, PhD; Fausto Feres, MD, PhD; Luiz A. Mattos, MD, PhD; Marinella Centemero, MD; Galo Maldonado, MD; Andrea S. Abizaid, MD; Ibraim Pinto, MD; Robert Falotico, PhD; Judith Jaeger, BA; Jeffrey J. Popma, MD; Patrick W. Serruys, MD, PhD

Background—We have previously reported the safety and effectiveness of sirolimus-eluting stents for the treatment of de novo coronary lesions. The present investigation explored the potential of this technology to treat in-stent restenosis.

Methods and Results—Twenty-five patients with in-stent restenosis were successfully treated with the implantation of 1 or 2 sirolimus-eluting Bx VELOCITY stents in São Paulo, Brazil. Nine patients received 2 stents (1.4 stents per lesion). Angiographic and volumetric intravascular ultrasound (IVUS) images were obtained after the procedure and at 4 and 12 months. All vessels were patent at the time of 12-month angiography. Angiographic late loss averaged 0.07±0.2 mm in-stent and −0.05±0.3 mm in-lesion at 4 months, and 0.36±0.46 mm in-stent and 0.16±0.42 mm in-lesion after 12 months. No patient had in-stent or stent margin restenosis at 4 months, and only one patient developed in-stent restenosis at 1-year follow-up. Intimal hyperplasia by 3-dimensional IVUS was 0.92±1.9 mm3 at 4 months and 2.55±4.9 mm3 after 1 year. Percent volume obstruction was 0.81±1.7% and 1.76±3.4% at the 4- and 12-month follow-up, respectively. There was no evidence of stent malapposition either acutely or in the follow-up IVUS images, and there were no deaths, stent thromboses, or repeat revascularizations.

Conclusion—This study demonstrates the safety and the potential utility of sirolimus-eluting Bx VELOCITY stents for the treatment of in-stent restenosis. (Circulation. 2003;107:24-27.)

Key Words: stents ☐ restenosis ☐ drugs ☐ angiography ☐ ultrasonics

Treating in-stent restenosis (ISR) has become one of the major challenges for the interventional cardiologist.1 Regardless of which percutaneous approach is chosen to treat an in-stent restenotic lesion (balloon angioplasty, stent, rotational atherectomy, or laser angioplasty), 30% to 80% of the patients will develop restenosis within the stent, at the stent edges, or both. Currently, the only proven effective therapy available for patients with ISR is intravascular brachytherapy.2 Unfortunately, this complex therapy carries with it the risks associated with ionizing radiation, including delayed endothelialization and potential late vascular thrombosis.3

The first-in-man (FIM) study has recently demonstrated the safety and effectiveness of sirolimus-eluting Bx VELOCITY stents for the treatment of single, de novo coronary lesions.4,5 In this somewhat benign population, no major clinical events (thrombosis, repeat revascularization, myocardial infarction, or death) occurred within 1-year of follow-up. Twelve months after the index procedure, neointimal proliferation and late lumen loss were virtually absent as determined both by quantitative intravascular ultrasound (IVUS) and angiography. Subsequently, the multicenter RAndomized study with the sirolimus-eluting Bx VELOCity balloon-expandable stent (RAVEL) study corroborated these results by reporting the absence of restenosis 6 months after the implantation of sirolimus-eluting stents in a similar subset of patients with de novo, single vessel, coronary artery disease.6 Whether such unparalleled results would be replicated in a more complex patient group, such as those with ISR, remains to be determined.

The aims of this pilot study were to determine the feasibility and safety of treating ISR with slow-release sirolimus-eluting Bx VELOCITY stents and to determine the impact of this technology on prevention of recurrent restenosis.

Methods

From March to June of 2001, 25 consecutive patients with ISR were successfully treated with the implantation of the sirolimus-eluting Bx

Received August 28, 2002; revision received October 28, 2002; accepted October 30, 2002.

From the Institute Dante Pazzanese of Cardiology, São Paulo, Brazil (J.E.S., A.A., A.G.M.R.S., F.F., L.A.M., M.C., G.M., A.S.A., I.P.); University of Florida-Shands, Jacksonville (M.A.C.); Cordis, a Johnson & Johnson Company, Warren, NJ (R.F., J.J.); Brigham and Women’s Hospital, Boston, Mass (J.J.P.); and Thoraxcenter, Dijkzigt University Hospital, Rotterdam, The Netherlands (P.W.S.).

Correspondence to Prof J. Eduardo Sousa, MD, PhD, Director of the Institute Dante Pazzanese of Cardiology, Av. Dr Dante Pazzanese, 500 - Ibirapuera, 04012180, São Paulo, Brazil. E-mail jesousa@uol.com.br

© 2003 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/01.CIR.0000047063.22006.41

24
VELOCTY stent. Stents were coated with 140 μg sirolimus/cm² per unit of metal surface area. The slow-release formulation (>28-day drug release) was used in this protocol. Patients were excluded if they had undergone previous intravascular radiation therapy to the target vessel, if the index lesion was >36 mm in length, or if the lesion was located in a saphenous vein graft.

Procedure
All stents were 18 mm long and varied from 2.5 to 3.5 mm in diameter. There was no ostial lesion treated in the present investigation. After predilatation of the target lesion, stents were deployed with high-pressure (>14 atmospheres) postdilatation, guided by IVUS to assure complete stent expansion, which was defined as in-stent minimal lumen area >80% of reference lumen area, and apposition. Debubbling devices were not used, and predilatation was performed with conventional balloon. The operator was allowed to implant up to 2 sirolimus-eluting stents to cover the entire length of the lesion, but coverage of the entire stented segment was not mandatory. Overlapping of the 2 adjacent sirolimus-eluting stents was recommended per the protocol. All patients received aspirin (325 mg/d, indefinitely) commencing at least 12 hours before the procedure and clopidogrel 300 mg immediately after stent implantation and 75 mg/d for 60 days thereafter. The protocol was approved by the Medical Ethical Committee and informed consent was obtained for every patient.

Quantitative Measurements
Postprocedure and 4- and 12-month quantitative coronary angiography (QCA) and IVUS imaging were performed in all patients. IVUS images were acquired using a motorized pullback at a constant speed of 0.5 mm/sec and volumetric quantification was performed. Quantitative angiographic and volumetric IVUS analyses were performed by independent Core laboratories (Brigham and Women’s Hospital, Boston, Mass and Cardialysis B.V, Rotterdam, The Netherlands, respectively). The three segments selected for volumetric IVUS analysis were the segment covered by sirolimus-eluting stents and 2 edge segments (axially 5 mm proximal and distal to the sirolimus-eluting stent margins). The presence of intimal hyperplasia in previously deployed stents and anatomical landmarks noted by angiography during stent deployment were used to guide IVUS selection of the segment covered by sirolimus-eluting stents.

As described previously, 2 coronary segments were subjected to quantitative angiography, in-stent and in-lesion segments. The in-stent analysis encompassed only the segment covered by sirolimus-eluting stent. The in-lesion segment was defined as the in-stent segment plus segments 5-mm proximal and 5-mm distal to the edge or the nearest side branch if the side branch was nearer than 5 mm from the stent edge. Contrast injection and angiography was performed after positioning the stent delivery system just before deployment. The relation between anatomic landmarks, including the previously deployed stents, and the 2 radiopaque markers of the delivery system were noted. In-stent and in-lesion restenosis were defined as >50% diameter stenosis (DS) at follow-up, located within the stent and target lesion, respectively. Minimal lumen diameter (MLD) and %DS were measured for each segment. In-lesion and in-stent late lumen loss (LL) were calculated as postprocedure MLD minus follow-up MLD. Validation of volumetric IVUS quantification has been described elsewhere.

Table 1. Quantitative Coronary Angiographic Analysis

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Preprocedure</th>
<th>Postprocedure</th>
<th>4-Month Follow-Up</th>
<th>12-Month Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>RD, mm</td>
<td>2.78±0.3</td>
<td>2.8±0.4</td>
<td>2.84±0.3</td>
<td>2.8±0.3</td>
</tr>
<tr>
<td>MLD, mm</td>
<td>1.05±0.3</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>DS, %</td>
<td>62.2±10.5</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Lesion length, mm</td>
<td>13.6±7.65</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>In-stent MLD, mm</td>
<td>...</td>
<td>2.71±0.3</td>
<td>2.64±0.4</td>
<td>2.35±0.6*</td>
</tr>
<tr>
<td>In-lesion MLD, mm</td>
<td>...</td>
<td>2.34±0.4</td>
<td>2.39±0.4</td>
<td>2.18±0.6†</td>
</tr>
<tr>
<td>In-stent DS, %</td>
<td>...</td>
<td>2.6±9</td>
<td>7.15±8.57</td>
<td>16.7±17.7</td>
</tr>
<tr>
<td>In-lesion DS, %</td>
<td>...</td>
<td>16.5±8.2</td>
<td>15.96±9.1</td>
<td>22.9±16.9</td>
</tr>
<tr>
<td>In-stent late loss, mm</td>
<td>...</td>
<td>0.07±0.2</td>
<td>0.36±0.46</td>
<td></td>
</tr>
<tr>
<td>In-lesion late loss, mm</td>
<td>...</td>
<td>−0.05±0.3</td>
<td>0.16±0.42</td>
<td></td>
</tr>
</tbody>
</table>

RD indicates reference diameter.
*P<0.001 for in-stent MLD postprocedure versus 12-month follow-up.
†P<0.001 for in-stent late loss 4-month versus 12-month follow-up.

Statistical Analysis
Continuous variables are expressed as mean±SD. Comparisons between postintervention and follow-up measurements were performed with a 2-tailed paired t test. A probability value <0.05 was considered statistically significant.

Results
The mean age was 56±12 years; 80% of the patients were male, and 24% were diabetics. Five patients (20%) had recurrent ISR. The time interval between initial bare metal stent implantation and development of in-stent restenosis varied from 3 to 7 months. Lesions were classified as focal (>10 mm) in 32%, diffuse intrastent in 40%, and diffuse proliferative in 28% of the patients according to previously reported classification. All stents were implanted successfully. Stent edge dissection was not detected either by angiography or IVUS and patients were discharged without complications 24 hours after treatment.

All patients were free of angina after 1 year, and there were no repeat revascularizations, stent thromboses, or major adverse clinical events (cerebrovascular accident, myocardial infarction, or death) during this time.

Angiographic data are presented in Table 1. At 4 months, in-stent lumen diameter remained essentially unchanged from postprocedure in 50% of the cases (Figure 1). Minimal angiography lumen gain observed in some patients may be explained by regression of intimal hyperplasia that was not covered with the sirolimus-eluting stent. There was a slightly but statistically significant decrease in in-stent MLD between 4 and 12 months (Table 1, Figure 1), whereas in-lesion MLD was essentially unchanged after 12 months (Table 1, Figure 1). Only 1 patient, who was asymptomatic, developed in-stent reste-
nosis at 12 months. IVUS imaging was not performed in this patient. IVUS analysis showed minimal neointimal hyperplasia volume (0.92±1.9 mm$^3$ at 4 months and 2.55±4.9 mm$^3$ at 12 months) in the remaining patients (Table 2).

**Discussion**

The present study demonstrates the feasibility of using sirolimus-eluting stents for the treatment of ISR. All patients were asymptomatic, and only 1 patient developed in-stent restenosis 12 months after treatment. In-stent intimal hyperplasia was minimal in most patients (Figure 2), and the in-lesion late loss was only 0.16-mm. Most importantly, the 12-month clinical follow-up was uneventful for all patients.

A number of clinical studies have documented the challenge of treating ISR because of the high recurrence of restenosis (30% to 80%).$^{1,8}$ which is directly related to the length of the ISR lesion and independent of device selection. Only recently has catheter-based intravascular brachytherapy become available as an effective treatment for patients with ISR.$^2$ Although intravascular brachytherapy trials have consistently shown a 40% to 70% reduction in re-restenosis as compared with placebo, there is still a 17% to 32% long-term failure rate for patients treated with brachytherapy.$^{2,9,10}$ The pioneer Scripps Coronary Radiation to Inhibit Proliferation Post Stenting (Scripps) study irradiated 26 patients (62% had ISR) using the Iridium-192 gamma-source.$^2$ Lesion length was <10 mm in 42% of the patients. Out of the 24 patients with complete angiographic follow-up, 17% had recurrent restenosis.

In the present study, in which 68% of the patients had diffuse ISR, there was no in-stent or edge restenosis 4 months after the implantation of sirolimus-eluting stents, and only 1 patient developed restenosis at 12 months. This patient had a

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Postprocedure</th>
<th>4-Month Follow-Up</th>
<th>12-Month Follow-Up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stented segment length, mm</td>
<td>21.6±7.4</td>
<td>21.6±7.5</td>
<td>21.9±7.34</td>
</tr>
<tr>
<td>Mean lumen area, mm$^2$</td>
<td>6.74±1.82</td>
<td>6.81±1.9</td>
<td>7.06±1.81</td>
</tr>
<tr>
<td>Percent obstruction volume, %</td>
<td>...</td>
<td>0.81±1.7</td>
<td>1.76±3.44</td>
</tr>
<tr>
<td>Peri-stent margins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distal mean lumen area, mm$^2$</td>
<td>7.04±2.5</td>
<td>7.27±2.7</td>
<td>7.24±2.43</td>
</tr>
<tr>
<td>Proximal mean lumen area, mm$^2$</td>
<td>7.46±2.39</td>
<td>8.2±2.78</td>
<td>8±2.59</td>
</tr>
<tr>
<td>Distal mean total vessel area, mm$^2$</td>
<td>12.64±5.16</td>
<td>12.69±4.94</td>
<td>12.99±5.15</td>
</tr>
<tr>
<td>Proximal mean total vessel area, mm$^2$</td>
<td>15.35±3.85</td>
<td>15.99±4.11</td>
<td>15.54±4.29</td>
</tr>
</tbody>
</table>

*Data do not include 1 patient with in-stent restenosis in whom the lesion could not be crossed with the IVUS catheter.
The lack of a control group clearly precludes a definitive scientific assessment of the excellent outcomes observed in the present study. The lack of stent thrombosis, repeat revascularization, myocardial infarction, or death in this patient population, however, indicates that the antiproliferative and antiinflammatory actions of sirolimus12 may provide a long-lasting antirestenosis effects after treatment of ISR lesions without the attendant risk of stent thrombosis observed with other effective treatment modalities. Longer-term follow-up will be required to determine whether the inhibition of in-stent restenosis observed in this study is sustained.

Although these data in a small cohort of patients are very encouraging, randomized controlled trials will be necessary to determine whether the reduction in late lumen loss, restenosis, and need for repeat intervention is indeed better than with brachytherapy, is sustained over several years, and can be achieved without the need for extended antiplatelet therapy.

Acknowledgments

We thank Drs Brian Firth and Dennis Donohoe for their careful review of the manuscript.

References

Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study


_Circulation_. 2003;107:24-27; originally published online December 2, 2002; doi: 10.1161/01.CIR.0000047063.22006.41

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/107/1/24

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/